Celine Poizat-Fournier

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 31 publications

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Machine Learning Prediction of Liver Fibrosis in Patients with Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD).

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: January 16, 2026

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

Journal: Nature medicine

Published: December 11, 2025

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Two-step clinical care pathway to predict MASLD-related advanced fibrosis and long-term outcomes in type 2 diabetes.

Journal: Gut

Published: November 06, 2025

Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular Risk.

Progression of Liver Fibrosis and Liver-Related Event Risk in MASLD at High Cardiovascular Risk.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 28, 2025

Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.

Progression of Liver Fibrosis and Liver-related Event Risk in Metabolic Dysfunction-associated Steatotic Liver Disease at High Cardiovascular Risk.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 28, 2025

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Journal: Lancet (London, England)

Published: September 17, 2025

One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

One-Year Changes in Liver Stiffness Measurement, but Not in Alanine Aminotransferase and Controlled Attenuation Parameter, Predict Long-Term Liver Outcomes in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: September 15, 2025

ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLD.

ONE-YEAR CHANGES IN LSM, BUT NOT IN ALT AND CAP, PREDICT LONG-TERM LIVER OUTCOMES IN PATIENTS WITH MASLD.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: September 15, 2025

Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD.

Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD.

Journal: Hepatology (Baltimore, Md.)

Published: September 12, 2025

Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD.

Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: September 11, 2025

Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review.

Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-The-Art Review.

Journal: Liver international : official journal of the International Association for the Study of the Liver

Published: August 12, 2025

Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement.

Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement.

Journal: Clinical and molecular hepatology

Published: August 06, 2025

Showing 1-12 of 31

Last Updated: 09/26/2026